Clinical efficacy of cytarabine + aclarubicin + recombinant human granulocyte colony-stimulating factor regimen combined with decitabine for adult acute myeloid leukemia

摘要

We aimed to analyze the efficacy of cytarabine + aclarubicin + recombinant human granulocyte colony-stimulating factor (G-CSF, i.e. CAG) regimen combined with decitabine in the clinical treatment of adult acute myeloid leukemia (AML). In total, 68 patients with adult AML were randomized into observation and control groups by random sampling. The control group (n = 34) was treated with CAG regimen alone and the observation group (n = 34) with CAG regimen combined with decitabine; the two groups were compared in terms of effective rate, incidence of adverse reactions, hemoglobin level, and blood progenitor cell and white blood cell counts. The observation and control groups exhibited a total effective rate of 85.29 and 61.76 after treatment, respectively (P < 0.05). During follow-up, recurrence and survival rates were 11.76 and 85.29 in the observation group and 32.36 and 61.76 in the control group, respectively (P < 0.05), indicating better results in the former group. CAG regimen combined with decitabine was superior to CAG regimen alone in treating adult AML. However, our study is limited by a small sample size, short follow-up period, few study indices, and low sufficiently representative results, warranting further studies.